Early Access — free while we kick the tires
EdgarHawk

Almenoff June Sherie

Director

Director
2 filings analyzed · 2 companies · Latest 2025-11-19

Companies

Company Buys Sells Direction
TENAX THERAPEUTICS, INC. TENX 2 0 Net buying
Avalo Therapeutics, Inc. AVTX 2 0 Net buying

Activity

November 2025
high
Buy
1,993 shares
$14,945
Significance 6/10

Director Almenoff purchases 1,993 shares in 2 transactions at blended avg $7.50; cluster buy with 2 other insiders in past 14 days

Director June Sherie Almenoff purchased 1,993 shares across 2 separate transactions totaling $14,944.78 at an average price of $7.50, establishing an initial stake in TENX. The purchase occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, which may indicate aligned appetite for the stock at current levels. Notably, TENX is unprofitable with a net income of $-15,804,000.00 and zero revenue in the latest quarter, operating from a market cap of $45,702,969.00. The stock is currently -6.5% from its 52-week high and has shown positive momentum over 30 and 90 days (+9.2% and +21.2% respectively), though Almenoff's cross-ticker track record shows an average 90-day return of +5.8% across all prior buys with a 100.00% win rate. The convergence of multiple insiders entering the stock during a recovery phase and amid significant operational losses warrants scrutiny of the company's near-term developments and capital position.

November 2024
high
Buy
1,000 shares
$12,750
Significance 6/10

Director Almenoff buys 1,000 shares at blended avg $12.75 on AVTX amid -89.3% annual revenue decline

Director June Sherie Almenoff made 2 separate purchases totaling 1,000 shares for $12,749.50 on consecutive days (November 12–13, 2024) at prices of $12.50 and $13.00 per share. This marks her first holdings in the company, establishing a 1,000-share position. The timing coincides with a 30-day price surge of +39.1% and a 90-day gain of +48.6%, yet the stock remains -43.2% below its 52-week high of $23.74. The fundamental backdrop is stark: annual revenue contracted by -89.3%, the company posted a full-year net loss, and latest quarterly revenue was only $249,000.00—indicating a severely distressed financial profile. The purchase at $12.75 blended price occurs in a deeply challenged operational environment, not at a recovery inflection point supported by earnings or revenue stabilization.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access